Crescendo enters collaboration to create cutting-edge oncology treatment
Cambridge-based Crescendo Biologics Ltd, the drug developer of novel, targeted T cell enhancing therapeutics has signed a pre-clinical collaboration agreement with Orano Med, a nuclear biotech company developing innovative targeted therapies in oncology.
Orano Med is developing a new generation of Targeted Alpha Therapies (TAT) using the unique properties of lead-212 (²¹²Pb), a rare radioisotope. Orano Med is generating novel therapeutics capable of specifically recognising and destroying cancer cells while limiting the impact on nearby healthy tissues, a cutting-edge treatment for cancers with high unmet need.
Crescendo and Orano Med are working to exemplify the benefit of using Humabody VH for precise targeting of Orano Med’s TAT.
Theodora Harold, CEO of Crescendo Biologics, said: “Orano Med is one of the leaders in the field of nuclear medicine. Collaborating on its Targeted Alpha Therapy is an exciting opportunity for Crescendo to demonstrate the advantages of Humabody VHs for exquisitely targeted delivery of a potent alpha-emitting payload.
“We welcome the opportunity to work with the team at Orano Med.”